Boletín informativo
de NYU sobre temas cardíacos
- A Publication of the Department of Cardiothoracic Surgery and Division of Interventional Cardiology, and Electrophysiology
Mejoras realizadas sobre el diseño de los stents
Norma Keller, MD, Assistant Clinical Professor of Medicine
Stents have revolutionized the world of interventional cardiology, particularly in regard to acute occlusion and restenosis. A major challenge was defining the role of stents in the setting of acute myocardial infarction (AMI). The Stent-PAMI (Randomized Trial of Primary PTCA versus heparin-coated stent implantation during acute myocardial infarction) trial compared percutaneous transluminal coronary angioplasty (PTCA) to stenting; and the CADILLAC (a randomized comparison of the ACS Multilink coronary stent system with or without abciximab versus PTCA with or without abciximab in the treatment of patients with acute myocardial infarction) trial, evaluated the administration of abciximab with primary PTCA or stenting during AMI. Prior to our participation in these studies, direct PTCA was the therapeutic strategy of choice at NYU Medical Center. We now still perform emergent cardiac catheterization for patients presenting with AMI, but then proceed with primary PCI (Percutaneous Coronary Intervention) and utilize stenting if feasible.
Since the introduction of coronary stents, there has been a movement to design newer and better stents. The BiodivYsio stent is a novel stent that is coated with phosphorylcholine. This biological coating appears to mimic the main lipid headgroup component of the natural cell membrane producing a non-activating biological interface. This was designed to improve the biocompatibility of stents. We were honored to have to have been selected as a site in the recently completed randomized international multicenter trial, Biocompatibles BiodivYsio Stent in Randomized Control Trial (DISTINCT), which compared this stent to the commercially available Duet stent. Although the BiodivYsio stents are not commercially available in the United States, we are fortunate to be one of 10 centers in the United States to participate in a Registry evaluating the 11 and 15 mm BiodivYsio stent in patients with symptomatic coronary artery disease due to de novo lesions.
- A Publication of the Department of Cardiothoracic Surgery and Division of Interventional Cardiology, and Electrophysiology
Mejoras realizadas sobre el diseño de los stents
Norma Keller, MD, Assistant Clinical Professor of MedicineStents have revolutionized the world of interventional cardiology, particularly in regard to acute occlusion and restenosis. A major challenge was defining the role of stents in the setting of acute myocardial infarction (AMI). The Stent-PAMI (Randomized Trial of Primary PTCA versus heparin-coated stent implantation during acute myocardial infarction) trial compared percutaneous transluminal coronary angioplasty (PTCA) to stenting; and the CADILLAC (a randomized comparison of the ACS Multilink coronary stent system with or without abciximab versus PTCA with or without abciximab in the treatment of patients with acute myocardial infarction) trial, evaluated the administration of abciximab with primary PTCA or stenting during AMI. Prior to our participation in these studies, direct PTCA was the therapeutic strategy of choice at NYU Medical Center. We now still perform emergent cardiac catheterization for patients presenting with AMI, but then proceed with primary PCI (Percutaneous Coronary Intervention) and utilize stenting if feasible.
Since the introduction of coronary stents, there has been a movement to design newer and better stents. The BiodivYsio stent is a novel stent that is coated with phosphorylcholine. This biological coating appears to mimic the main lipid headgroup component of the natural cell membrane producing a non-activating biological interface. This was designed to improve the biocompatibility of stents. We were honored to have to have been selected as a site in the recently completed randomized international multicenter trial, Biocompatibles BiodivYsio Stent in Randomized Control Trial (DISTINCT), which compared this stent to the commercially available Duet stent. Although the BiodivYsio stents are not commercially available in the United States, we are fortunate to be one of 10 centers in the United States to participate in a Registry evaluating the 11 and 15 mm BiodivYsio stent in patients with symptomatic coronary artery disease due to de novo lesions.